RecruitMe Clinical Trial
Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation (ACES) PBMTC SUP1701
Off the shelf T-cells therapy for viral infection post HCST
Sponsor: | Pediatric Bone Marrow Transplant Consortium |
Enrolling: | Male and Female Patients |
Study Length: | 3 Years |
IRB Number: | AAAR8071 |
Contact: | Jean Sosna, RN: 212-305-2050 / js4403@cumc.columbia.edu |
Additional Study Information:
In this trial, we will evaluate whether partially-HLA matched allogeneic multivirus-specific VSTs, will be safe and produce anti-viral effects in immunodeficient recipients infected with one of more of the targeted viruses that are persistent despite conventional anti-viral therapy. This will be in patients who have received a hematopoietic stem cell transplant or patients with primary immunodeficiency conditions who have persistent viral infections and have not undergone HSCT.
This study is closed